Publications
Deep Learning-Based Disease Severity Biomarkers on Computed Tomography: Post Hoc Analysis in a Phase 2a Placebo-Controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
Presented at the American Thoracic Society 2025 International Conference
Anita DiFrancesco1, John Hood1, Miguel de los Rios1, Miguel Monterio2, Elliott Bussell2, Muhunthan Thillai2, Simon LF Walsh2,3
1. Endeavor BioMedicines, San Diego, CA, United States; 2. Qureight Ltd, Cambridge, United Kingdom; 3. National Heart and Lung Institution, Imperial College, United Kingdom
WHISTLE-PF: Study Design of a Phase 2b, Multi-Center, Randomized, Double-Blind Controlled Trial of ENV-101 (Taladegib) in Patients With Idiopathic Pulmonary Fibrosis
Presented at the American Thoracic Society 2025 International Conference
T. M. Maher, MD, MSc, PhD, FRCP1; P. Molyneaux, PhD2; J. G. Goldin, MD, PhD3; J. C. Huetsch, MD4; A. DiFrancesco, BSc4; J. Hood, PhD4; M. de los Rios, PhD4; J. Gibbs, MPH4
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States; 2. Royal Brompton Hospital, London, United Kingdom; 3. David Geffen School of Medicine at UCLA, Santa Monica, CA, United States; 4. Endeavor BioMedicines, San Diego, CA, United States
Hedgehog Pathway Inhibition Improves Lung Function and Reduces Lung Fibrosis in Patients with IPF: Results from a Randomized, Double-blind, Placebo-controlled Phase 2 Trial of ENV-101
Presented at the 22nd International Colloquium on Lung and Airway Fibrosis 2024
T. M. Maher,1 J. G. Goldin,2 A. DiFrancesco,3 M. de los Rios,3 C. Quito,3 S. Kim,3 E. Bizjak,3 J. Hood3
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States 2. David Geffen School of Medicine at UCLA, Santa Monica, CA, United States 3. Endeavor BioMedicines, San Diego, CA, United States
ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial
Presented at the American Thoracic Society 2024 International Conference
T. M. Maher1, J. G. Goldin2, A. DiFrancesco3, M. de los Rios3, C. Quito3, S. Kim3, P. A. Frohna3, J. Hood3
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States 2. David Geffen School of Med At UCLA, Santa Monica, CA, United States 3. Endeavor BioMedicines, San Diego, CA, United States